Loading organizations...
§ Private Profile · Munich, Germany
AI platform automating drug launch workflows for pharmaceutical companies, focused on pricing, market access, and regulatory data.
Cellbyte has raised $2.8M across 1 funding round.
Key people at Cellbyte.
Cellbyte was founded in 2024 by Felix Steinbrenner (Co-Founder & CEO).
Cellbyte has raised $2.8M in total across 1 funding round.
Based in Munich, Germany, Cellbyte develops an artificial intelligence platform that helps pharmaceutical companies accelerate commercial drug launches by automating complex pricing, market access, and regulatory workflows. The software-as-a-service business utilizes tools like document intelligence and agentic workflows to integrate over 100 data sources, generating actionable competitive intelligence across 12 key global markets. Operating with a core team of three employees, the startup rapidly achieved six figures in annual recurring revenue by securing enterprise software contracts with major pharmaceutical clients such as Bayer. To support planned international expansion into the United States and triple its headcount, the firm raised $2.75 million in seed funding led by Frontline Ventures, alongside participation from Y Combinator and Pace Ventures. Cellbyte was founded in 2024 by co-chief executive officers Felix Steinbrenner and Daniel Moreira, alongside co-founder Samuel.
Cellbyte has raised $2.8M across 1 funding round. Most recently, it raised $2.8M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 18, 2025 | $2.8M Seed | William Mcquillan | Pace Ventures, Saras Capital, Springboard Health Angels, TOM Blomfield | Announced |
Key people at Cellbyte.
Cellbyte is a Munich-based AI-native platform that accelerates pharmaceutical drug launches by automating complex workflows involved in regulatory preparation, pricing, market access, and launch sequencing. Its system analyzes millions of real-time data points from clinical, pricing, HTA (Health Technology Assessment), regulatory, and internal corporate sources to provide fast, reliable insights that compress months-long processes into minutes without sacrificing quality. This enables pharmaceutical companies to optimize go-to-market strategies and regulatory submissions efficiently. Cellbyte serves major global pharmaceutical firms, including Bayer, and has rapidly gained traction, reaching six-figure ARR shortly after launch and expanding internationally with plans to triple its headcount and scale engineering capabilities[1][2][3].
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte emerged from the founders’ combined expertise in pharmaceutical consulting, AI/machine learning engineering, and startup operations. Daniel Moreira brought deep industry insight from his years at Simon-Kucher, a leading life sciences consultancy, identifying inefficiencies in pricing and market access workflows. Felix Steinbrenner, a repeat founder and Y Combinator alumnus, contributed operational leadership and enterprise sales experience, while Samuel Moreira provided technical AI expertise from his background at Celonis. The founders’ long-standing collaboration and shared vision to modernize pharma drug launches through generative AI led to Cellbyte’s creation and early success, including securing seed funding of $2.75 million led by Frontline Ventures and contracts with top pharma companies[1][2][5].
Cellbyte rides the wave of AI-driven transformation in life sciences, particularly in pharmaceutical commercial operations where data complexity and regulatory demands have traditionally slowed drug launches. The timing is critical as generative AI matures, enabling deeper, faster insights from vast, heterogeneous datasets that legacy systems cannot handle effectively. Market forces such as increasing pressure to reduce time-to-market, optimize pricing strategies, and navigate complex global regulatory environments favor solutions like Cellbyte. By modernizing drug launch workflows, Cellbyte not only accelerates patient access to new treatments but also pushes the pharmaceutical ecosystem toward data-driven, AI-augmented decision-making, setting a new standard for operational efficiency and strategic agility[1][2][3].
Looking ahead, Cellbyte is positioned to become the core operating system for commercial pharmaceutical teams worldwide, scaling its engineering and expanding its international footprint. Trends shaping its journey include continued advances in AI, growing demand for real-time, integrated market intelligence, and increasing complexity in global drug pricing and reimbursement landscapes. As Cellbyte deepens its platform capabilities and broadens its customer base, its influence will likely extend beyond launch acceleration to encompass broader lifecycle management and strategic commercial planning in pharma. This evolution will reinforce its role as a critical enabler of faster, smarter drug commercialization in the AI era[1][2][3].
Cellbyte was founded in 2024 by Felix Steinbrenner (Co-Founder & CEO).
Cellbyte has raised $2.8M in total across 1 funding round.
Cellbyte's investors include William McQuillan, Pace Ventures, Saras Capital, Springboard Health Angels, Tom Blomfield.
